INVIVYD INC
IVVDNASDAQTrading Snapshot
- Day Range
- $0.60 – $0.64
- 52-Week Range
- $0.53 – $3.07
- Volume (shares)
- 694,385
- Avg Volume (shares)
- —
- Shares Outstanding
- 294.8M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $53M
- Last Q Revenue
- $14M
- P/E Ratio
- -1.5
- P/S Ratio
- 3.0x
- EPS (TTM)
- $-0.33
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +45.3%
INVIVYD INC
IVVD
StockOtter · stockotter.spaceAbout INVIVYD INC
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated potent in vitro antiviral activity against contemporary measles virus variant
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
NEW HAVEN, Conn., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) and the SPEAR Study Group today announced the initiation of FLINTLOCK, a Phase 2 clinical trial evaluating the safety, tolerability, pharma
Invivyd’s VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval
Invivyd (NASDAQ: IVVD) reported topline results from its Phase III LIBERTY study of VYD2311, an investigational low-dose intramuscular monoclonal antibody designed to prevent COVID-19, and outlined plans to pursue an acc
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on October 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase an aggregate of 157,50
Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval
Invivyd NASDAQ: IVVD reported topline results from its Phase III LIBERTY study of VYD2311, an investigational low-dose intramuscular monoclonal antibody designed to prevent COVID-19, and outlined plans to pursue an accel
Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody
Invivyd Inc. (NASDAQ:IVVD) on Tuesday announced topline results from its Phase 3 LIBERTY study of its investigational COVID-19 monoclonal antibody candidate.